ALX Oncology Holdings Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ALXO Nasdaq 2836 www.alxoncology.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for ALX Oncology Holdings Inc.

3 Promising Penny Stocks With Market Caps Over $100M - Feb 10th, 2026 5:05 am
Is ALX Oncology Holdings (ALXO) Stock Outpacing Its Medical Peers This Year? - Feb 9th, 2026 7:40 am
ALX Oncology Announces Pricing of Underwritten Offering - Jan 30th, 2026 6:30 am
New Data Demonstrate CD47 Expression Level Helps Predict Response to ALX Oncology’s Evorpacept in Combination with Ziihera (zanidatamab-hrii) in Advanced HER2-Positive Breast Cancer - Jan 30th, 2026 6:15 am
ALX Oncology Spotlights Evorpacept HER2 Strategy and EGFR ADC ALX2004 Progress at JPM Conference - Jan 15th, 2026 3:17 pm
ALX Oncology Holdings Leads Our Selection Of 3 Promising Penny Stocks - Jan 12th, 2026 11:05 am
ALX Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference - Jan 8th, 2026 9:00 am
ALX Oncology Advances Separate Clinical Trials Evaluating Investigational CD47-Inhibitor Evorpacept and Novel EGFR-Targeted Antibody-Drug Conjugate ALX2004 - Jan 8th, 2026 6:30 am
ALX Oncology Announces Positive Results from Ongoing Investigator-Sponsored Phase 2 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with Indolent B-cell Non-Hodgkin Lymphoma, at ASH Annual Meeting - Dec 7th, 2025 6:00 am
ALX Oncology to Present at Upcoming Investor Conferences - Nov 18th, 2025 9:00 am
ALX Oncology Holdings Inc (ALXO) Q3 2025 Earnings Call Highlights: Promising Clinical Advances ... - Nov 8th, 2025 12:05 am
ALX Oncology Reports Third Quarter 2025 Financial Results and Provides Corporate Update - Nov 7th, 2025 6:15 am
ALX Oncology to Report Third Quarter 2025 Financial Results and Pipeline Progress Including Evorpacept CD47 Biomarker Data to be Presented at Upcoming SITC Annual Meeting - Oct 30th, 2025 6:30 am
ALX Oncology Announces Preclinical Data and Phase 1 Trial-in-Progress Presentations of ALX2004, a Novel EGFR-Targeted ADC, at 2025 AACR-NCI-EORTC Conference - Oct 23rd, 2025 10:30 am
Is Alnylam Pharmaceuticals (ALNY) Outperforming Other Medical Stocks This Year? - Oct 14th, 2025 7:40 am
ALX Oncology to Present Updated Data from Phase 2 ASPEN-06 Trial, Highlighting CD47 Expression as a Predictive Biomarker in HER2+ Gastric Cancer, at 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting - Oct 3rd, 2025 7:05 am
3 Promising Penny Stocks With Market Caps Under $700M - Sep 25th, 2025 12:05 pm
CEO & Director of ALX Oncology Holdings Picks Up 69% More Stock - Sep 21st, 2025 6:39 am
ALX Oncology Appoints Board Member Barbara Klencke, M.D., as Interim Chief Medical Officer - Sep 12th, 2025 6:30 am
ALX Oncology to Participate in Upcoming Investor Conferences in September - Aug 29th, 2025 10:00 am